Anhedonia Beyond Depressive Symptoms in Children and Adolescents With Conduct Disorder
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Conduct Disorder (CD) is a common psychiatric disorder among children and adolescents and is characterized by a persistent pattern of behaviors that violate the rights of others or major age-appropriate social norms and rules. Although CD is traditionally classified as an externalizing disorder, evidence suggests that some affected adolescents also show abnormalities in emotional and motivational processing, particularly in reward and punishment responsiveness. Anhedonia, defined as reduced ability to experience pleasure, is traditionally considered a core symptom of depression but is increasingly recognized as a transdiagnostic construct that may reflect disturbances in reward processing. Importantly, altered reward responsiveness is not synonymous with clinical anhedonia, and clinically measured anhedonia in adolescents with CD remains insufficiently characterized. Depressive symptoms may contribute to anhedonia and therefore require assessment and statistical control. ADHD is also frequently comorbid with CD and may independently influence reward processing and motivation. Callous-Unemotional traits may additionally overlap with emotional blunting. Therefore, the present study will compare anhedonia in adolescents with CD with or without comorbid ADHD, and healthy controls, while accounting for depressive symptoms and relevant clinical covariates.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 24, 2026
CompletedFirst Posted
Study publicly available on registry
September 30, 2026
CompletedStudy Start
First participant enrolled
October 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
ExpectedSeptember 30, 2026
September 1, 2026
Same day
September 24, 2026
September 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
SHAPS total score
SHAPS total score, representing overall anhedonia severity
baseline
Study Arms (2)
cases group
Participants meeting criteria for Conduct Disorder
control group
healthy control
Eligibility Criteria
Participants aged 12-17 years will be recruited consecutively from the outpatient child and adolescent psychiatry service. Participants meeting criteria for Conduct Disorder will form the clinical group. Healthy controls of comparable age, sex, and socioeconomic status will be recruited from community or school settings. ADHD comorbidity will be assessed within the Conduct Disorder group
You may qualify if:
- Age 12-17 years.
- CD groups: meeting DSM-5 criteria for Conduct Disorder confirmed using the Arabic K-SADS-PL-C DSM-5.
- Control group: no current or previous psychiatric diagnosis according to the Arabic K-SADS-PL-C DSM-5.
- Ability to understand and complete the assessment procedures.
- Written informed consent from a parent/legal guardian and written assent from the adolescent.
You may not qualify if:
- Intellectual disability or severe cognitive impairment interfering with reliable assessment.
- Autism spectrum disorder or severe neurodevelopmental disorder interfering with self-report.
- Current psychotic disorder.
- Current or past bipolar I disorder or manic episode.
- Current major depressive episode meeting full diagnostic criteria.
- Current severe substance use disorder.
- Known neurological disorder, including epilepsy or severe traumatic brain injury.
- Major uncontrolled medical condition likely to substantially affect mood or hedonic functioning.
- Current medication expected to substantially affect reward processing or anhedonia, where clinically relevant.
- Acute suicidal risk or psychiatric condition requiring immediate crisis intervention/hospitalization.
- Refusal to participate or inability to complete the assessment. Stable stimulant treatment for ADHD may be permitted when clinically necessary and will be recorded as a covariate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- residant doctor at Assiut university hospital
Study Record Dates
First Submitted
September 24, 2026
First Posted
September 30, 2026
Study Start
October 1, 2026
Primary Completion
October 1, 2026
Study Completion (Estimated)
December 1, 2027
Last Updated
September 30, 2026
Record last verified: 2026-09